Literature DB >> 30858505

Gene regulation by antitumor miR-130b-5p in pancreatic ductal adenocarcinoma: the clinical significance of oncogenic EPS8.

Haruhi Fukuhisa1, Naohiko Seki2, Tetsuya Idichi1, Hiroshi Kurahara1, Yasutaka Yamada3, Hiroko Toda1, Yoshiaki Kita1, Yota Kawasaki1, Kiyonori Tanoue1, Yuko Mataki1, Kosei Maemura1, Shoji Natsugoe1.   

Abstract

Our ongoing analyses identifying dysregulated microRNAs (miRNAs) and their controlled target RNAs have shed light on novel oncogenic pathways in pancreatic ductal adenocarcinoma (PDAC). The PDAC miRNA signature obtained by RNA sequencing showed that both strands of pre-miR-130b (miR-130b-5p, the passenger strand and miR-130b-3p, the guide strand) were significantly downregulated in cancer tissues. Our functional assays revealed that miR-130b-5p significantly blocked the malignant abilities of PDAC cell lines (PANC-1 and SW1990), e.g., cancer cell proliferation, migration, and invasion. A total of 103 genes were identified as possible oncogenic targets by miR-130b-5p regulation in PDAC cells based on genome-wide gene expression analysis and in silico database search. Among the possible targets, high expression of 9 genes (EPS8, ZWINT, SMC4, LDHA, GJB2, ZCCHC24, TOP2A, ANLN, and ADCY3) predicted a significantly poorer prognosis of PDAC patients (5-year overall survival, p < 0.001). Furthermore, we focused on EPS8 because its expression had the greatest impact on patient prognosis (overall survival, p < 0.0001). Overexpression of EPS8 was detected in PDAC clinical specimens. Knockdown assays with siEPS8 showed that its overexpression enhanced cancer cell proliferation, migration, and invasion. Analysis of downstream RNA networks regulated by EPS8 indicated that MET, HMGA2, FERMT1, RARRES3, PTK2, MAD2L1, and FLI1 were closely involved in PDAC pathogenesis. Genes regulated by antitumor miR-130b-5p were closely involved in PDAC molecular pathogenesis. Our approach, discovery of antitumor miRNAs and their target RNAs, will contribute to exploring the causes of this malignant disease.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30858505     DOI: 10.1038/s10038-019-0584-6

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  15 in total

1.  Identification of ITPR1 as a Hub Gene of Group 3 Medulloblastoma and Coregulated Genes with Potential Prognostic Values.

Authors:  Pablo Ferreira das Chagas; Graziella Ribeiro de Sousa; Luciana Chain Veronez; Andrea Martins-da-Silva; Carolina Alves Pereira Corrêa; Gustavo Alencastro Veiga Cruzeiro; Luis Fernando Peinado Nagano; Rosane Gomes de Paula Queiroz; Suely Kazue Nagahashi Marie; Silvia Regina Brandalise; Carlos Alberto Scrideli; Luiz Gonzaga Tone; Elvis Terci Valera
Journal:  J Mol Neurosci       Date:  2021-11-25       Impact factor: 3.444

Review 2.  Noncoding RNA actions through IGFs and IGF binding proteins in cancer.

Authors:  Aidan Kerr; Robert C Baxter
Journal:  Oncogene       Date:  2022-05-21       Impact factor: 8.756

3.  Heterogeneous Effects of Calorie Content and Nutritional Components Underlie Dietary Influence on Pancreatic Cancer Susceptibility.

Authors:  James Dooley; Vasiliki Lagou; Jermaine Goveia; Anna Ulrich; Katerina Rohlenova; Nathalie Heirman; Tobias Karakach; Yulia Lampi; Shawez Khan; Jun Wang; Tom Dresselaers; Uwe Himmelreich; Marc J Gunter; Inga Prokopenko; Peter Carmeliet; Adrian Liston
Journal:  Cell Rep       Date:  2020-07-14       Impact factor: 9.423

4.  Involvement of Dual Strands of miR-143 (miR-143-5p and miR-143-3p) and Their Target Oncogenes in the Molecular Pathogenesis of Lung Adenocarcinoma.

Authors:  Hiroki Sanada; Naohiko Seki; Keiko Mizuno; Shunsuke Misono; Akifumi Uchida; Yasutaka Yamada; Shogo Moriya; Naoko Kikkawa; Kentaro Machida; Tomohiro Kumamoto; Takayuki Suetsugu; Hiromasa Inoue
Journal:  Int J Mol Sci       Date:  2019-09-11       Impact factor: 5.923

5.  A novel 20-gene prognostic score in pancreatic adenocarcinoma.

Authors:  Seçil Demirkol Canlı; Ege Dedeoğlu; Muhammad Waqas Akbar; Barış Küçükkaraduman; Murat İşbilen; Özge Şükrüoğlu Erdoğan; Seda Kılıç Erciyas; Hülya Yazıcı; Burçak Vural; Ali Osmay Güre
Journal:  PLoS One       Date:  2020-04-20       Impact factor: 3.240

6.  Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients.

Authors:  Sandra Roche; Fiona O'Neill; Jean Murphy; Niall Swan; Justine Meiller; Neil T Conlon; Justin Geoghegan; Kevin Conlon; Ray McDermott; Rozana Rahman; Sinead Toomey; Ninfa L Straubinger; Robert M Straubinger; Robert O'Connor; Gerard McVey; Michael Moriarty; Martin Clynes
Journal:  Int J Mol Sci       Date:  2020-01-31       Impact factor: 5.923

7.  Effects and mechanisms of Eps8 on the biological behaviour of malignant tumours (Review).

Authors:  Kaili Luo; Lei Zhang; Yuan Liao; Hongyu Zhou; Hongying Yang; Min Luo; Chen Qing
Journal:  Oncol Rep       Date:  2021-01-07       Impact factor: 3.906

8.  Construction of an mRNA-miRNA-lncRNA network prognostic for triple-negative breast cancer.

Authors:  Yuan Huang; Xiaowei Wang; Yiran Zheng; Wei Chen; Yabing Zheng; Guangliang Li; Weiyang Lou; Xiaojia Wang
Journal:  Aging (Albany NY)       Date:  2021-01-03       Impact factor: 5.682

9.  Inherited variations in human pigmentation-related genes modulate cutaneous melanoma risk and clinicopathological features in Brazilian population.

Authors:  Gustavo Jacob Lourenço; Cristiane Oliveira; Benilton Sá Carvalho; Caroline Torricelli; Janet Keller Silva; Gabriela Vilas Bôas Gomez; José Augusto Rinck-Junior; Wesley Lima Oliveira; Vinicius Lima Vazquez; Sergio Vicente Serrano; Aparecida Machado Moraes; Carmen Silvia Passos Lima
Journal:  Sci Rep       Date:  2020-07-22       Impact factor: 4.379

10.  Role of miR-30a-3p Regulation of Oncogenic Targets in Pancreatic Ductal Adenocarcinoma Pathogenesis.

Authors:  Hiroki Shimomura; Reona Okada; Takako Tanaka; Yuto Hozaka; Masumi Wada; Shogo Moriya; Tetsuya Idichi; Yoshiaki Kita; Hiroshi Kurahara; Takao Ohtsuka; Naohiko Seki
Journal:  Int J Mol Sci       Date:  2020-09-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.